The departure of FDA Commissioner Marty Makary from his position has prompted commentary from his predecessor, former FDA Commissioner Scott Gottlieb, who shared his analysis of what this change could mean for the Trump administration’s healthcare policies.
Gottlieb offered his insights into how Makary’s exit from the Food and Drug Administration might influence the direction of health-related initiatives under the current administration.
The resignation represents a significant shift in leadership at the federal agency responsible for regulating food, drugs, and medical devices across the United States.
